Abstract 214P
Background
Urothelial carcinoma (UC), including upper tract UC (UTUC) and UC of the bladder (UCB), is one of the most common malignancies worldwide. The current standard methods for diagnosis and monitoring of UC are often invasive and/or lack sensitivity and specificity. Emerging evidence has shown that urinary RNAs could potentially serve as promising biomarkers for UC diagnosis. In this study, we intended to develop and validate an accurate and noninvasive urine RNA test for UC diagnosis and monitoring.
Methods
Gene expression profiling of our previously reported 32 RNA targets were analyzed TaqMan qPCR arrays. We pooled all samples analyzed before to obtain a larger training set and develop a diagnostic gene panel. The identified gene panel was then validated in a large-scale independent cohort of 752 patients. Voided urine specimens were prospectively collected at 3 hospitals from subjects scheduled for tumor surgery or endoscopy for the urinary tract due to suspicious symptoms. The sensitivity and specificity of the gene panel were evaluated using endoscopy and/or histologic diagnosis as a reference.
Results
An eight-gene panel (CA9, CCL18, ERBB2, IGF2, MMP12, PPP1R14D, SGK2 and SWINGN) was developed. In the prospective cohort, the gene panel achieved 93.4%overall accuracy (702/752), 92.3% sensitivity (275/298) and 94.1% specificity (427/454). High sensitivity was maintained in low grade (89.9%, 62/69), early stage (88.5%, 115/130) and residual tumors (89.5%, 34/38). Notably, the gene panel accurately detected UTUCs with 97.3% (36/37) sensitivity, indicating that urinary RNA targets selected here were relevant markers for both UTUC and UCB. Besides, the specificity among other malignancies like prostate cancer, renal cancer, etc. reached 94.5% (173/183). With respect to surveillance, the gene panel showed 88.6% sensitivity and 98.2% specificity for detecting recurrences in 136 patients.
Conclusions
In summary, the eight-gene urine test showed superior sensitivity and specificity for diagnosis of UCs across all tumor stages, grades and sites, hence might represent a promising tool for noninvasive UC detection and surveillance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Canhelp Genomics.
Disclosure
Y. Wo, Z. Luo, J. Chen, Q. Xu: Financial Interests, Personal, Full or part-time Employment: Canhelp Genomics. All other authors have declared no conflicts of interest.
Resources from the same session
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract
297P - The utilization rate of radiotherapy and chemotherapy for cervical cancer in Indonesia: Optimal versus actual, how far the gap?
Presenter: Charity Kotambunan
Session: Poster Display
Resources:
Abstract